Drug Trial Radar · NCT04511624
Single Dose Tolerability and Pharmacokinetics of IBI112 in Healthy Subjects
Last checked: Nov 19, 2026Latest source record: Sep 19, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
46
Actual
Start
Aug 27, 2020
Primary completion
Jul 22, 2022
Study completion Jul 22, 2022
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 13, 2020
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 45 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a the first in human study to evaluate the safety, tolerability, PK and PD of single subcutaneous or intravenous dose of IBI112 in healthy subjects
Conditions
- Healthy Subjects
Interventions
IBI112 dose1Drug
Drug: IBI112 SC dose1 Drug:placebo
IBI112 dose2Drug
Drug: IBI112 SC dose2 Drug:placebo
IBI112 dose3Drug
Drug: IBI112 SC dose3 Drug:placebo
IBI112 dose4Drug
Drug: IBI112 SC dose4 Drug:placebo
IBI112 dose5Drug
Drug: IBI112 IV dose5 Drug:placebo
IBI112 dose6Drug
Drug: IBI112 SC dose6 Drug:placebo
IBI112 dose7Drug
Drug: IBI112 IV dose7 Drug:placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events in healthy volunteers with single ascending doses of IBI112Time frame: Day1 to Day 113 post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Huashan Hospital Affiliated to Fudan University
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.